Elekta AB (publ) (OTCMKTS:EKTAY – Get Rating) saw a significant decrease in short interest in April. As of April 30th, there was short interest totalling 8,500 shares, a decrease of 50.9% from the April 15th total of 17,300 shares. Based on an average daily volume of 77,000 shares, the short-interest ratio is presently 0.1 days.
Several brokerages have issued reports on EKTAY. JPMorgan Chase & Co. reduced their price target on shares of Elekta AB (publ) from SEK 79 to SEK 69 and set an “underweight” rating on the stock in a report on Tuesday, April 26th. Zacks Investment Research downgraded shares of Elekta AB (publ) from a “hold” rating to a “sell” rating in a report on Wednesday. Danske downgraded shares of Elekta AB (publ) from a “buy” rating to a “hold” rating in a report on Tuesday, February 15th. Finally, Jefferies Financial Group began coverage on shares of Elekta AB (publ) in a report on Thursday, January 20th. They issued an “underperform” rating on the stock.
Shares of OTCMKTS:EKTAY traded up $0.19 during trading on Friday, reaching $7.01. The stock had a trading volume of 26,836 shares, compared to its average volume of 41,157. The business has a fifty day moving average price of $7.50 and a 200-day moving average price of $9.85. The company has a quick ratio of 0.95, a current ratio of 1.17 and a debt-to-equity ratio of 0.52. The stock has a market cap of $2.58 billion, a P/E ratio of 20.62 and a beta of 1.04. Elekta AB has a fifty-two week low of $6.24 and a fifty-two week high of $15.56.
The company also recently disclosed a dividend, which was paid on Friday, March 18th. Stockholders of record on Monday, February 28th were given a $0.0805 dividend. This represents a dividend yield of 2.67%. The ex-dividend date was Friday, February 25th. Elekta AB (publ)’s dividend payout ratio is presently 44.12%.
Elekta AB (publ) Company Profile (Get Rating)
Elekta AB (publ), a medical technology company, provides clinical solutions for cancer and brain disorders worldwide. The company offers radiotherapy treatment systems, such as Versa HD, a dose delivery accuracy system; Elekta Infinity, an image-guided radiation therapy (IGRT) system; and Elekta Synergy, a digital accelerator for advanced IGRT.
- Get a free copy of the StockNews.com research report on Elekta AB (publ) (EKTAY)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Elekta AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elekta AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.